Comvita Limited · NZX:CVT
Comvita — H1 FY2016 Earnings Presentation
23 slides from Comvita's earnings presentation, November 2015
Slide 1: Investor Presentation November 2015
INVESTOR PRESENTATION November 2015 Chairman, Neil Craig, 021 731 509 CEO, Sco: Coulter, 021 386 988 CFO, Mark Sadd, 027 707 9698
Slide 2: Key Achievements
Investor Presentation November 2015 KEY ACHIEVEMENTS Sales growth Record first half Secured honey Investment in New CEO for of 53% net earnings of supply with SeaDragon to next stage of compared to $3m. Up $6.3m significant honey strengthen our growth first half of compared to first stocks available ing
Slide 3: Half Year Financial Highlights
Investor Presentation November 2015 HALF YEAR FINANCIAL HIGHLIGHTS Financial results for the 6 months to 2015 2014 30 September $’000 $’000 Revenue 91,066 59,615 EBITDA* 10,176 201 Net profit (loss) a_er tax 3,040 (3,261) Earnings per share (cents per share) 7.69 (10.27) Dividends (cents per share) 6
Slide 4: Financial Performance
Investor Presentation November 2015 FINANCIAL PERFORMANCE $190-‐$200m*** $32-‐$35m*** Group Revenue EBITDA** $23.0m $153m $17.0m $115m $103m $15.5m $14.7m $96m $85m $82m $11.2m $71m $57m* $6.3m $39m $5.3m $4.8m $0.4m* Projec'on Projec'on 2006 2008 2009 2010 2011 2012 2013 2014 2015 2016 2006 2008
Slide 5: Key Balance Sheet Ratios
Investor Presentation November 2015 KEY BALANCE SHEET RATIOS Half year comparison Year end 30/09/2015 30/09/2014 31/03/2015 Total assets $215m $175m $200m Raw material inventory $42m $22m $28m Net debt $60m $63m $26m Net debt to equity raRo 52% 72% 22% 5
Slide 6: Comvita Strategy
Investor Presentation November 2015 COMVITA STRATEGY Earnings Focus Security of Supply InnovaRon MarkeRng Spend AcquisiRons Concentrate on ConRnued OpRmising Increasing Focus on earnings growth development of ingredient market market spend to earnings supply chain and channel grow our added accreRve
Slide 7: Experienced Leadership
Investor Presentation November 2015 EXPERIENCED LEADERSHIP Sco: Coulter Chief ExecuRve Officer Mark Sadd Roy Ong Patrick Brus Colin Baskin TBA Chief Financial Chief MarkeRng Chief Corporate Chief Supply Chief InnovaRon Officer & Sales Officer Services Officer Chain Officer Officer 7
Slide 8: Market Segments
Investor Presentation November 2015 MARKET SEGMENTS Comvita manufactures, markets and distributes natural health products across four key broad market segments 26% of total 65% of total 4% of total 5% of total revenue revenue revenue revenue HEALTHCARE FUNCTIONAL FOODS PERSONAL CARE MEDICAL 44% Grow
Slide 9: Sales Growth by Segment
Investor Presentation November 2015 SALES GROWTH BY SEGMENT MEDICAL EUROPE 106% 8% ASIA Sales Growth Sales Growth 53% $4.7m $4.3m Sales Growth $30.3m AUSTRALIA 77% Sales Growth $28.7m NZ 33% Sales Growth $19.7m Figures are based on 6 months to 30 September 2015 9
Slide 10: Value Added
Investor Presentation November 2015 VALUE ADDED $5 $14(5+) $250 $330 $500 $104(20+) GENERIC COMVITA BRANDED LOZENGES MEDICAL SKINCARE HEALTH HONEY Retail selling price per 250g equivalent of raw Manuka honey 10
Slide 11: Comvita Value Model
Investor Presentation November 2015 COMVITA VALUE MODEL 11
Slide 12: Building a Premium Global Brand
Investor Presentation November 2015 BUILDING A PREMIUM GLOBAL BRAND Brand reputaRon Brand offer Brand story ReputaRon for Growth and in Asia allows focussed on value creates a unique heritage, awareness significant price add to ingredient premium natural trusted source opportunity premium over plaUorm
Slide 13: Consumer Engagement
Investor Presentation November 2015 CONSUMER ENGAGEMENT • Highly moRvated to achieve wellness goals • Wellness pressures driven by environmental and social factors create demand for natural preventaRve health soluRons: • Ageing populaRon • PopulaRon density and polluRon • Food safety • Growing healt
Slide 14: Innovation
Investor Presentation November 2015 INNOVATION • Circa $2.8m p.a. in research and development • FDA approved and CE marked medical devices • A total of 77 patents or patents pending covering 19 different, unique innovaRons around wound care, product analysis, quality control and selected product heal
Slide 15: Owning and Optimising Manuka Honey
Investor Presentation November 2015 OWNING AND OPTIMISING MANUKA HONEY • Plant breeding programmes • Leading Manuka culRvar development • Advanced agronomic research • 33,000 hive apiary operaRon • Apiarist training programme • Bespoke Apiary Management System (AMS); traceability, opRmised yield, ad
Slide 16: Supply Chain Excellence: Manuka Honey
Investor Presentation November 2015 SUPPLY CHAIN EXCELLENCE MANUKA HONEY • Demand driven supply chain • Centralised demand planning • Global forecasRng so_ware • Auto market replenishment planning • Make to forecast • Traceability to hive • Structured Sales and OperaRons Processes • Global warehousi
Slide 17: Supply Chain Excellence: Fresh Olive Leaf
Investor Presentation November 2015 SUPPLY CHAIN EXCELLENCE FRESH OLIVE LEAF • Approximately one million olive trees • 100% Australian grown, natural fresh olive leaf; fully integrated same day harvest to process • Natural pest management systems • Established plant selecRon processes • ‘Gentle’ har
Slide 18: Our Story
Investor Presentation November 2015 OUR STORY 18
Slide 19: Manuka Honey
Investor Presentation November 2015 MANUKA HONEY 19
Slide 20: Propolis
Investor Presentation November 2015 PROPOLIS 20
Slide 21: Fresh Olive Leaf Complex
Investor Presentation November 2015 FRESH OLIVE LEAF COMPLEX 21
Slide 22: Winter Wellness
Investor Presentation November 2015 WINTER WELLNESS 22
Slide 23: Medihoney
Investor Presentation November 2015 MEDIHONEY 23